IM Cannabis Signs Definitive Agreement to Sell European Assets to CEO-Controlled Entity
IMCC is trading near its 52-week low of $0.097 (6.1% below the low) on light trading volume (0.1× avg).
Summary
IM Cannabis signed a definitive agreement to sell its European operations to a company controlled by its CEO, receiving C$3M in advance payments and transferring up to C$9.4M in liabilities, with an expected C$3M equity improvement.
Key Events · M&A and Partnerships · IMCC
-
Definitive Agreement Signed
On August 16, 2026, IM Cannabis entered into a definitive share purchase agreement to sell 100% of IMC Holdings (European assets) to Slil.com Holding Ltd., controlled by CEO Oren Shuster.
-
Consideration and Liability Transfer
The consideration includes a C$3.0 million advance payment already received and Slil's assumption of retained liabilities capped at C$9.4 million, for an aggregate of approximately C$12.4 million.
-
Equity Improvement Expected
The transaction is expected to improve shareholders' equity by approximately C$3.0 million and reduce debt, addressing the company's going concern and Nasdaq delisting risk.
-
Related Party Transaction
Because Slil is controlled by CEO Oren Shuster, the deal is a related party transaction under MI 61-101; the company is relying on financial hardship exemptions from formal valuation and minority approval.
Analysis · IMCC · Life Sciences
The June 18 non-binding letter of intent has now been converted into a definitive share purchase agreement, under which IM Cannabis will sell its European-focused assets to Slil.com Holding Ltd., a company controlled by CEO Oren Shuster. This related party transaction transfers IMC Holdings—which holds Adjupharm GmbH, Xinteza API Ltd., and Shiran Societe Anonyme—to Slil in exchange for a C$3.0 million advance payment already received and Slil's assumption of up to C$9.4 million in retained liabilities. The company expects the deal to improve shareholders' equity by approximately C$3.0 million and reduce debt, offering much-needed relief given the going concern doubts and Nasdaq delisting risk disclosed just days ago. However, the related party nature and reliance on financial hardship exemptions under MI 61-101 raise governance concerns, and the transaction must close by September 30, 2026.
How filings like this one have moved
In the 30 days to Oct 20, 2026, 37.4% of the 952 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.87%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMCC was trading at $0.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1M. The 52-week trading range was $0.10 to $2.83. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.